RT Journal Article
SR Electronic
T1 A proteomic survival predictor for COVID-19 patients in intensive care
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.24.21259374
DO 10.1101/2021.06.24.21259374
A1 Vadim Demichev
A1 Pinkus Tober-Lau
A1 Tatiana Nazarenko
A1 Simran Kaur Aulakh
A1 Harry Whitwell
A1 Oliver Lemke
A1 Annika Röhl
A1 Anja Freiwald
A1 Mirja Mittermaier
A1 Lukasz Szyrwiel
A1 Daniela Ludwig
A1 Clara Correia-Melo
A1 Lena J. Lippert
A1 Elisa T. Helbig
A1 Paula Stubbemann
A1 Nadine Olk
A1 Charlotte Thibeault
A1 Nana-Maria Grüning
A1 Oleg Blyuss
A1 Spyros Vernardis
A1 Matthew White
A1 Christoph B. Messner
A1 Michael Joannidis
A1 Thomas Sonnweber
A1 Sebastian J. Klein
A1 Alex Pizzini
A1 Yvonne Wohlfarter
A1 Sabina Sahanic
A1 Richard Hilbe
A1 Benedikt Schaefer
A1 Sonja Wagner
A1 Felix Machleidt
A1 Carmen Garcia
A1 Christoph Ruwwe-Glösenkamp
A1 Tilman Lingscheid
A1 Laure Bosquillon de Jarcy
A1 Miriam S. Stegemann
A1 Moritz Pfeiffer
A1 Linda Jürgens
A1 Sophy Denker
A1 Daniel Zickler
A1 Claudia Spies
A1 Andreas Edel
A1 Nils B. Müller
A1 Philipp Enghard
A1 Aleksej Zelezniak
A1 Rosa Bellmann-Weiler
A1 Günter Weiss
A1 Archie Campbell
A1 Caroline Hayward
A1 David J. Porteous
A1 Riccardo E. Marioni
A1 Alexander Uhrig
A1 Heinz Zoller
A1 Judith Löffler-Ragg
A1 Markus A. Keller
A1 Ivan Tancevski
A1 John F. Timms
A1 Alexey Zaikin
A1 Stefan Hippenstiel
A1 Michael Ramharter
A1 Holger Müller-Redetzky
A1 Martin Witzenrath
A1 Norbert Suttorp
A1 Kathryn Lilley
A1 Michael Mülleder
A1 Leif Erik Sander
A1 PA-COVID-19 Study group
A1 Florian Kurth
A1 Markus Ralser
YR 2021
UL http://medrxiv.org/content/early/2021/06/26/2021.06.24.21259374.abstract
AB Global healthcare systems are challenged by the COVID-19 pandemic. There is a need to optimize allocation of treatment and resources in intensive care, as clinically established risk assessments such as SOFA and APACHE II scores show only limited performance for predicting the survival of severely ill COVID-19 patients. Comprehensively capturing the host physiology, we speculated that proteomics in combination with new data-driven analysis strategies could produce a new generation of prognostic discriminators. We studied two independent cohorts of patients with severe COVID-19 who required intensive care and invasive mechanical ventilation. SOFA score, Charlson comorbidity index and APACHE II score were poor predictors of survival. Plasma proteomics instead identified 14 proteins that showed concentration trajectories different between survivors and non-survivors. A proteomic predictor trained on single samples obtained at the first time point at maximum treatment level (i.e. WHO grade 7) and weeks before the outcome, achieved accurate classification of survivors in an exploratory (AUROC 0.81) as well as in the independent validation cohort (AUROC of 1.0). The majority of proteins with high relevance in the prediction model belong to the coagulation system and complement cascade. Our study demonstrates that predictors derived from plasma protein levels have the potential to substantially outperform current prognostic markers in intensive care.Trial registration German Clinical Trials Register DRKS00021688Competing Interest StatementThe authors have declared no competing interest.Clinical TrialDRKS00021688Funding StatementThis work was supported by the Berlin University Alliance (501-Massenspektrometrie, 501-Linklab, 112-PreEP-Corona-Ralser), by UKRI/NIHR through the UK Coronavirus Immunology Consortium (UK-CIC), the BMBF/DLR Projektträger (01KI20160A, 01ZX1604B, 01KI20337, 01KX2021), Charité-BIH Centrum für Therapieforschung (BIH-PA-covid-19-Ralser), the BBSRC (BB/N015215/1, BB/N015282/1), the Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001134), the UK Medical Research Council (FC001134), and the Wellcome Trust (FC001134 and IA 200829/Z/16/Z). The work was further supported by the Ministry of Education and Research (BMBF), as part of the National Research Node Mass spectrometry in Systems Medicine (MSCoresys), under grant agreement 031L0220A. Leif Erik Sander is supported by the German Research Foundation (DFG, SFB-TR84 114933180) and by the Berlin Institute of Health (BIH), which receives funding from the Ministry of Education and Research (BMBF). Martin Witzenrath is supported by grants from the German Research Foundation, SFB-TR84 C06 and C09, by the German Ministry of Education and Research (BMBF) in the framework of the CAPSyS (01ZX1304B), CAPSyS-COVID (01ZX1604B), SYMPATH (01ZX1906A) and PROVID project (01KI20160A) and by the Berlin Institute of Health (CM-COVID). Stefan Hippenstiel is supported by the German Research Foundation (DFG, SFB-TR84 A04 and B06), and the BMBF (PROVID, and project 01KI2082). Norbert Suttorp is supported by grants from the German Research Foundation, SFB-TR84 C09 und Z02, by the German Ministry of Education and Research (BMBF) in the framework of the PROGRESS 01KI07114. The study was further supported by Wellcome Trust (200829/Z/16/Z). The Generation Scotland study received core support from the Chief Scientist Office of the Scottish Government Health Directorates (CZD/16/6) and the Scottish Funding Council (HR03006), and is now supported by the Welcome Trust (216767/Z/19/Z). Archie Campbell is funded by HDR UK and the Wellcome Trust (216767/Z/19/Z). Caroline Hayward is supported by an MRC University Unit Programme Grant (MC-UU-00007/10) (QTL in Health and Disease). Riccardo Marioni is supported by an Alzheimer s Research UK project grant (ARUK-PG2017B-10). H. Whitwell, JF. Timms, A. Zaikin and T. Nazarenko are supported by a Medical Research Council grant (MR/R02524X/1) and H. Whitwell, A. Zaikin and O. Blyuss by the Ministry of Science and Higher Education agreement No. 075-15-2020-808. H. Whitwell is supported by the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre (BRC). J. Timms is supported by the National Institute for Health Research (NIHR) UCLH/UCL Biomedical Research Centre. Mirja Mittermaier is a participant in the BIHCharité Digital Clinician Scientist Program funded by the Charité — Universitätsmedizin Berlin, the Berlin Institute of Health, and the German Research Foundation (DFG). Markus A. Keller is supported by the Austrian Science Funds (FWF; P33333) and the Austrian Research Promotion Agency (FFG, #878654). Figures were created with biorender.com.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the ethics committee of Charité - Universit?auml;tsmedizin Berlin (EA2/066/20)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe protein quantities table along with the associated metadata are provided in supplementary materials. All scripts used to train and assess the machine learning models are likewise provided.